Arcus Biosciences to Provide a Mid-Year Update on Clinical and Preclinical Programs

Company to Host Conference Call and Live Webcast on Tuesday, June 25, 2019 at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time

Arcus Biosciences, Inc. RCUS, a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that the Company will host a conference call and live webcast on Tuesday, June 25, 2019, at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time to provide a mid-year update on its clinical and preclinical programs.

Investors interested in listening to the conference call may do so by dialing (866) 211-3164 in the U.S. or (647) 689-6573 internationally, using Conference ID: 7163128.

To access the live webcast and accompanying slide presentation, please visit the "Investors" section of the Arcus website at www.arcusbio.com. Following the live webcast, a replay will be available on the Company's website for approximately 30 days.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies. Arcus has several programs targeting important oncology/immuno-oncology pathways, including a dual adenosine receptor antagonist, AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody, AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus's other product candidates. Arcus's other programs include AB154, an anti-TIGIT antibody, which is being evaluated in a Phase 1 trial as monotherapy and in combination with AB122, and AB680, a small-molecule inhibitor of CD73, which is in a Phase 1 healthy volunteer study. Arcus has extensive in-house expertise in medicinal chemistry, oncology, immunology, biochemistry, pharmacology and structural biology. Utilizing these unique capabilities, Arcus has developed a robust and active early stage discovery effort focused on small-molecule pipeline expansion. For more information about Arcus Biosciences, please visit www.arcusbio.com.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!